CA
NZ
UK
AU
IND
US
Agios Pharmaceuticals (NASDAQ: AGIO) shares closed down 7% at $37.36 after the company revealed Phase 2 data for tebapivat in sickle cell disease (SCD) and announced it would halt the program.
Vyne Therapeutics (NASDAQ: VYNE) shares closed up 11% at $0.89 after the company convened a special meeting of shareholders to deliberate on a proposal to merge with Yarrow.
A cluster of biopharma names moved sharply on a single day of corporate, clinical, and regulatory news, with eight companies posting double-digit or high-single-digit share price swings tied to distinct, company-specific catalysts spanning commercial deals, trial results, mergers, and shareholder votes.
PolyPid Ltd. (NASDAQ: PYPD) shares fell 27% to close at $3.74 despite the company establishing a sole commercial partnership with Azurity Pharmaceuticals to market and distribute D-PLEX100 in the U.S. and Canada, targeting the prevention of abdominal surgical site infections.
Lisata Therapeutics (NASDAQ: LSTA) shares closed down 36% at $2.24, reaching their lowest point in almost half a year, following a breach of contract by Kuva Labs.
Celldex Therapeutics (NASDAQ: CLDX) shares are down 7% at $33.05 during extended hours after the company shared primary findings from a Phase 2 trial investigating subcutaneous barzolvolimab for prurigo nodularis (PN).
Marpai (OTC: MRAI) has renegotiated its AXA agreement, reducing scheduled debt service by $26.4 million and deferring the offering‑proceeds fee until the company secures $5 million from securities offerings. Under the revised schedule, the firm is required to make a $0 payment in 2026, …
Microbot Medical is set to engage with the medical and investment communities at an upcoming industry event, where CEO Harel Gadot will participate in a discussion on neurovascular robotics. The session, part of the Society of Robotic Surgery 2026 program, offers a platform for …
Novo Nordisk has launched a legal offensive against Eli Lilly, accusing its rival of misleading advertising in the fiercely competitive GLP-1 drug market. The lawsuit, filed in an unspecified court, seeks a permanent injunction to halt Lilly’s promotional campaigns and demands corrective advertising to …
The Pentagon’s decision to introduce testosterone replacement therapy (TRT) screening for troops over 30 is sending ripples through the healthcare and defense sectors, with investors weighing the potential benefits against unanswered risks. The move, aimed at male service members without a diagnosed deficiency, has …
Please wait processing your request...